Deep Dives into Peptide Science
Research breakdowns, protocol design, and the latest findings from the world of peptide science. Written for researchers who care about the evidence.
Retatrutide Cut Weight by 25% in 80 Weeks. The Knee Pain and Sleep Apnea Data Matter More.
The full Phase 3 retatrutide results just landed in NEJM and The Lancet. The weight numbers are historic. The trial's hidden endpoints, knee arthritis pain and sleep apnea, are what make this drug different.
TERN-601 Lost 4.6% More Weight Than Placebo. Three Liver Cases Ended the Program.
A peer-reviewed Phase 2 trial explains why the oral GLP-1 candidate TERN-601 was discontinued: modest weight loss, high dropout, and three delayed liver-enzyme cases.
GLP-1 Drugs Were Linked to 26% Less Dementia in High-Risk Adults. The Alzheimer’s Trials Still Failed.
A new study found lower dementia incidence in adults with diabetes and mild cognitive impairment. It is promising observational evidence, not proof of prevention.
Ribupatide’s First Human Paper Reports 9.6% Weight Loss in Four Weeks. The Trial Was Tiny.
A new peer-reviewed Phase 1 paper puts hard numbers behind ribupatide, a weekly dual GLP-1/GIP peptide. The strongest result is striking, but eight-person dose groups and four weeks of treatment leave the real obesity question open.
Avexitide Cut Dangerous Low-Blood-Sugar Events by 55%. Full Phase 3 Data Are Still Missing.
A 78-person Phase 3 trial found 55% fewer Level 2 and Level 3 hypoglycemic events with avexitide. The signal is strong, but the complete dataset is not public.
Vosoritide Added 2.33 cm a Year in Hypochondroplasia. Adult Height Is Still Unknown.
A phase 3 trial found that vosoritide increased growth velocity in children with hypochondroplasia. The one-year result is strong, but adult height and long-term safety remain unknown.
Personalized Peptide Vaccines Activated T Cells in Pancreatic Cancer. They Did Not Prove Longer Survival.
Two personalized vaccine platforms activated mutation-specific T cells after pancreatic-cancer surgery. The 20-person phase 1 evidence does not yet show longer survival.
A 10-Day Course of Nerve Growth Factor Eye Drops Was Followed for Four Years. It Did Not Prove a Lasting Effect.
A four-year follow-up found stable vision and MRI scans after an experimental 10-day NGF eye-drop trial. The result supports tolerability, not lasting efficacy.
Stopping Semaglutide Changed Glucose Control in Type 1 Diabetes. The Study Was Small.
A 12-week ADJUST-T1D extension found less time in range and greater glucose variability after semaglutide withdrawal. The signal matters, but the study included only 16 people who stopped treatment.
A Peptide PET Scan Detected Cardiac Amyloidosis With 94% Sensitivity. The Hard Part Comes Next.
A phase 3 trial found 124I-evuzamitide PET/CT detected cardiac amyloidosis with 94% sensitivity. Here is what the scan can—and cannot—prove.
An Oral Relaxin Mimic Changed Heart-Failure Hemodynamics. The Hard Endpoint Is Still Missing.
A 375-person phase 2b trial found that oral RXFP1 agonist AZD5462 changed heart-failure hemodynamics, but clinical benefit remains unproven.